Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Amazon is hawking dubious health products, including some that have been criticized by regulators and may even be illegal.
PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018.
Teva’s stock jumped as investors get more hopeful about the future.
In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results.
The company said it received the letter on November 9 based on an inspection of its facilities from April and that it is preparing an appropriate response to the letter.
Acorda Therapeutics updated its Phase III clinical trial of tozadenant for Parkinson’s disease.
We write about science every day, why isn’t it getting through to the public consciousness?
The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
The FDA issued warning letters to Lupin for two of its manufacturing facilities in Goa and Pithampur, Indore.
The company is pulling these particular devices due to the number of complaints that it received relating to partial stent deployment.